Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The study, sponsored by the National Institutes of Health, will gather data on tecovirimat, or TPOXX.
I’m grateful I can apply so many of the painful lessons from my past to help diminish the impact of this new pandemic.
How HIV long-term survivors contribute to a better future for everyone
The process toward a creating a healthier lifestyle and discovering my genotype.
An update from co-chairs of the A5345 study conducted by AIDS Clinical Trials Group Network.
A trio of Sustiva (efavirenz)-free combinations of antiretrovirals each worked well as a first-line treatment for HIV, although there were dif...
People with HIV starting treatment regimens containing Sustiva have a more than doubled risk of suicidal thoughts, attempts and completed atte...
HIV-Positive women respond well to the human papillomavirus (HPV) vaccine, even when they have a low CD4 count.
Sustiva (efavirenz) doubles the rate of suicidality among those starting therapy for the first time, although the overall risk remains minimal...
How pharmaceutical and biotech companies are playing a major role in the search for an HIV cure.
People taking abacavir (found in Ziagen, Epzicom and Trizivir) had no greater risk of having a heart attack than people not taking abacavir, a...
There is a 40 percent higher risk of virologic failure among blacks, compared with whites, who are starting HIV treatment for the first time,...
Women living with HIV who’ve gone through menopause do just as well when starting antiretroviral (ARV) therapy for the first time, compared wi...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.